NASDAQ · ENTO
Entero Therapeutics, Inc.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
Loading market information…
NASDAQ · OMGA · USD
Stock price, earnings
Quote as of Feb 24, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Omega Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Omega Therapeutics, Inc. functions as a biopharmaceutical firm in its development phase. Its innovative OMEGA Epigenomic Programming platform leverages epigenetics—nature's fundamental system for gene regulation and cell differentiation—to engineer therapeutic solutions. The company is advancing various omega epigenomic controller (OEC) candidates to tackle a spectrum of diseases. These candidates are designed to enhance the expression of HNF4a, a crucial transcriptional master regulator, aiming to restore liver cell function in patients with chronic liver ailments. They also work to promote corneal regeneration in those with diabetes and other conditions by regulating genes associated with inhibiting cell growth. Furthermore, OECs are being developed to reduce the expression of the CXCL1, 2, 3, and IL-8 gene cluster for inflammatory diseases, and to manage gene expression implicated in idiopathic pulmonary fibrosis, seeking to arrest or reverse disease progression and improve patient outcomes. Other targets include down-regulating SFRP1, a protein known to hinder hair growth, and addressing both non-small cell and small cell lung cancers. Additionally, Omega Therapeutics is progressing OTX-2002, an investigational treatment intended to diminish the activity of c-Myc, an oncogene. Incorporated in 2016, the company's main operations are based in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 3, 2023 | -$0.54-5.88% vs estimate | $759.00K+100.49% vs estimate |
|---|
| Q1 2023 | May 4, 2023 | -$0.50+21.88% vs estimate | $516.00K+64.18% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$1.35+$0.09 (+7.14%)
Channel Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.51% below the high.
$0.36$0.00 (0.0%)
Turnstone Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.3% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
$0.94-$0.01 (-0.53%)
Fresh Tracks Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.44% below the high.
